Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript August 7, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals Inc. (PHAT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,250,497 | $21,582,266 | +331% | 0.01% |
| 2. | 683 Capital Partners Ari Zweiman | 2,105,000 | $20,186,950 | +46% | 1.33% |
| 3. | Avidity Partners Management David Witzke And Michael Gregory | 1,064,500 | $10,208,555 | +34% | 2.03% |
| 4. | Propel Bio Management Leen Kawas And Richard Kayne | 922,927 | $8,850,870 | -19% | 10.74% |
| 5. | Catalio Capital Management George Petrocheilos And R. Jacob Vogelstein | 672,290 | $6,447,261 | 1.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.86 | 3,780 | $14,609.32 | 59,403 | 2025-05-21 | Filing | |
| $3.32 | 6,300 | $20,919.15 | 55,623 | 2025-05-14 | Filing | |
| $3.16 | 1,120 | $3,543.34 | 49,323 | 2025-05-13 | Filing | |
| $3.04 | 12,601 | $38,300.74 | 48,203 | 2025-05-12 | Filing | |
| $3.62 | 2,226 | $8,053.00 | 35,602 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.36 | 1,692 | $14,151.72 | 48,392 | 2025-07-16 | Filing | |
| $4.55 | 3,678 | $16,739.68 | 89,868 | 2025-04-07 | Filing | |
| $6.59 | 6,583 | $43,370.78 | 93,546 | 2025-01-21 | Filing | |
| $6.59 | 7,886 | $51,956.91 | 233,390 | 2025-01-21 | Filing | |
| $6.59 | 19,109 | $125,884.36 | 360,465 | 2025-01-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,466,489 | $119,553,630 | 4.78% | |
| 2. | 7,464,572 | $71,585,245 | 16.75% | |
| 3. | 4,140,072 | $39,703,290 | 0.01% | |
| 4. | 3,496,808 | $33,534,389 | 0.67% | |
| 5. | 3,315,348 | $31,794,187 | 0% |
News See All
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript May 1, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Earnings Call Transcript
Operator: Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
12 Most Shorted Stocks in 2024
Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that is required...
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.8, expectations were $-0.92.
Hedge Fund and Insider Trading News: Amber Capital UK LLP, Third Point LLC, D.E. Shaw, Odey Asset Management, Alameda Research, North Rock Digital, FedEx Corp (FDX), Domo, Inc. (DOMO), and More
Amber Capital UK LLP founder Joseph Oughourlian denied a news report that claimed he was in talks with several private equity funds to take control of Spanish defense group Indra Sistemas SA.
Billionaire Hedge Funds
